A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of 10 Days of Repeat Dosing of GSK1521498 in Overweight or Obese But Otherwise Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2017
At a glance
- Drugs GSK 1521498 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 23 Mar 2010 Actual patient number (49) added as reported by ClinicalTrials.gov.
- 23 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History